ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 882,77
-0,30%
Dow Jones
44 556,04
0,30%
DAX
21 409,00
-0,47%
Brent Oil
75,395
-0,72%
Bitcoin
97 911,90
0,06%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. MannKind Corporation (MNKD)

  7. MannKind Corporation (MNKD) Actualités

MNKD

MannKind (MNKD)

MannKind Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MNKD
DateHeureSourceTitreSymboleSociété
30/01/202503h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
06/01/202523h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
06/01/202522h30GlobeNewswire Inc.MannKind Expands Executive Leadership TeamNASDAQ:MNKDMannKind Corporation
18/12/202413h00GlobeNewswire Inc.MannKind Corporation Announces Exchange of Convertible Notes for Stock and CashNASDAQ:MNKDMannKind Corporation
16/12/202412h05GlobeNewswire Inc.MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)NASDAQ:MNKDMannKind Corporation
11/12/202412h00GlobeNewswire Inc.CDSCO Approves Afrezza® (insulin human) Inhalation Powder in IndiaNASDAQ:MNKDMannKind Corporation
26/11/202403h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
22/11/202422h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
07/11/202422h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNKDMannKind Corporation
07/11/202422h02GlobeNewswire Inc.MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business UpdateNASDAQ:MNKDMannKind Corporation
05/11/202422h15GlobeNewswire Inc.MannKind to Present at 2024 UBS Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
04/11/202412h05GlobeNewswire Inc.MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic DiseasesNASDAQ:MNKDMannKind Corporation
31/10/202421h05GlobeNewswire Inc.MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024NASDAQ:MNKDMannKind Corporation
30/09/202412h00GlobeNewswire Inc.More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)NASDAQ:MNKDMannKind Corporation
18/09/202412h15GlobeNewswire Inc.MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
10/09/202422h30GlobeNewswire Inc.MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
27/08/202422h30GlobeNewswire Inc.MannKind to Present at Upcoming ConferencesNASDAQ:MNKDMannKind Corporation
14/08/202414h00GlobeNewswire Inc.Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the BoardNASDAQ:MNKDMannKind Corporation
07/08/202414h00GlobeNewswire Inc.MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
07/08/202411h49IH Market NewsUS Index Futures Rise Amid Earnings Season Optimism, Oil Prices ReboundNASDAQ:MNKDMannKind Corporation
31/07/202412h30GlobeNewswire Inc.MannKind Launches Educational Website to Raise Awareness of NTM Lung DiseaseNASDAQ:MNKDMannKind Corporation
30/07/202422h30GlobeNewswire Inc.MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024NASDAQ:MNKDMannKind Corporation
22/06/202414h00GlobeNewswire Inc.INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific SessionsNASDAQ:MNKDMannKind Corporation
05/06/202412h45GlobeNewswire Inc.Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific SessionsNASDAQ:MNKDMannKind Corporation
29/05/202414h45GlobeNewswire Inc.MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With PulmatrixNASDAQ:MNKDMannKind Corporation
08/05/202422h18GlobeNewswire Inc.MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
06/05/202412h05GlobeNewswire Inc.MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
01/05/202422h00GlobeNewswire Inc.MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024NASDAQ:MNKDMannKind Corporation
30/04/202412h05GlobeNewswire Inc.MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesNASDAQ:MNKDMannKind Corporation
29/04/202412h05GlobeNewswire Inc.MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
 Showing the most relevant articles for your search:NASDAQ:MNKD

Dernières Valeurs Consultées

EU
DG
Vinci
NASDAQ
AMZN
Amazon.com
EU
RI
Pernod Ricard
EU
AI
Air Liquide
EU
ORA
Orange
NYSE
DIS
Walt Disney
EU
PX1
CAC 40
NYSE
KO
Coca Cola
EU
HO
Thales
COIN
ETHUSD
Ethereum
EU
ML
Michelin
EU
CS
Axa
EU
AF
Air FranceKLM
COIN
XRPUSD
Ripple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces